PAC-1 (first procaspase activating compound) is a synthesized chemical compound that selectively induces apoptosis, in cancerous cells. [note 1] It was granted orphan drug status by the FDA in 2016.

One unit is defined as the amount of enzyme required to digest 1 µg of pNEB193 DNA in 1 hour at 37°C in a total reaction volume of 50 µl. Not sensitive to CpG, dcm, or dam methylation. How can the efficieny of PacI be increased? Is PacI inhibited by salt? What is …

Aiding in the diagnosis of paraneoplastic neurological autoimmune disorders related to carcinoma of lung, breast, ovary, thymoma, or Hodgkin lymphoma using spinal fluid specimens.

2020年1月13日 · PAC1 is selectively upregulated in exhausted tumor-infiltrating lymphocytes and is associated with poor prognosis of patients with cancer. PAC1 hi effector T cells lose their proliferative and...

Pituitary adenylate cyclase-activating polypeptide type I receptor also known as PAC1, is a protein that in humans is encoded by the ADCYAP1R1 gene. [5] . This receptor binds pituitary adenylate cyclase activating peptide. [6][7]

PAC-1 induces the activation of procaspase-3 in vitro and in cell culture by chelation of inhibitory labile zinc ions via its ortho -hydroxy- N -acylhydrazone moiety. First reported in 2006, PAC-1 has shown promise in cell culture and animal models of cancer, and a Phase I clinical trial in cancer patients began in March 2015 (NCT02355535).

Pituitary adenylyl cyclase activating polypeptide (PACAP) belongs to the vasoactive intestinal polypeptide (VIP)/secretin/glucagon superfamily. PACAP is present in two forms (PACAP-38 and PACAP-27) and binds to three guanine-regulatory (G) …

2024年9月17日 · Phosphatase of activated cells 1 (PAC1), also known as dual-specificity phosphatase 2 (DUSP2), belongs to the nuclear-localized DUSPs and is selectively expressed in immune cells, especially lymphoid cells (26 – 29). Our previous research has demonstrated the key role of PAC1 in limiting the effector functions of T cell subsets.

2022年12月5日 · Procaspase-3 (PC-3) is overexpressed in multiple tumour types and procaspase-activating compound 1 (PAC-1) directly activates PC-3 and induces apoptosis in cancer cells. This report describes...

Procaspase-3 (PC-3) is overexpressed in multiple tumour types and procaspase-activating compound 1 (PAC-1) directly activates PC-3 and induces apoptosis in cancer cells. This report describes the first-in-human, phase I study of PAC-1 assessing maximum tolerated dose, safety, and pharmacokinetics.